Evidence map›Paper›PMID 36738751›Full record

Trial reportThe lancet. Diabetes & endocrinology2023

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.

Lori M Laffel, Thomas Danne, Georgeanna J Klingensmith, William V Tamborlane, Steven Willi, Philip Zeitler, Dietmar Neubacher, Jan Marquard, DINAMO Study Group

Open access · greenAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 5 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Prediabetes in children and adolescents: what do we need to know?Annals of pediatric endocrinology & metabolism · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 10 institutions in 2 countries.

Lori M LaffelJoslin Diabetes Center, Harvard Medical School, Boston, MA, USA. Electronic address: lori.laffel@joslin.harvard.edu.
Thomas DanneAuf der Bult Kinder-und Jugendkrankenhaus, Hannover, Germany.
Georgeanna J KlingensmithBarbara Davis Center, University of Colorado, Aurora, CO, USA.
William V TamborlaneYale University, New Haven, CT, USA.
Steven WilliPerelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, PA, USA.
Philip ZeitlerChildren's Hospital Colorado, Aurora, CO, USA.
Dietmar NeubacherBoehringer Ingelheim, Biberach, Germany.
Jan MarquardBoehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.
DINAMO Study Group
University of Colorado Anschutz Medical Campus · USYale University · USBoehringer Ingelheim (Germany) · DEBoehringer Ingelheim (United States) · USChildren's Hospital Colorado · USChildren's Hospital of Philadelphia · USHarvard University · USJoslin Diabetes Center · USKinderkrankenhaus auf der Bult · DEUniversity of Pennsylvania · US

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

backgroundThe incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycaemic control in young people with type 2 diabetes.

methodsIn this double-blind, placebo-controlled trial done in 108 centres in 15 countries, participants with type 2 diabetes (aged 10-17 years; HbA

findingsBetween April 26, 2018, and May 26, 2022, of 262 screened participants, 158 (60%) were randomly assigned to treatment (53 [34%] to placebo, 52 [33%] to empagliflozin 10 mg, and 53 [34%] to linagliptin). For the primary outcome, the adjusted mean HbA

interpretationEmpagliflozin provided clinically relevant placebo-corrected reductions in HbA

fundingThe Boehringer Ingelheim and Eli Lilly and Company Alliance.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemiaSodium-Glucose Transporter 2 InhibitorsAdolescentBenzhydryl CompoundsBlood GlucoseChildDouble-Blind MethodGlucosidesHumansHypoglycemic AgentsLinagliptinTreatment OutcomeBenzhydryl CompoundsBlood GlucoseDipeptidyl-Peptidase IV InhibitorsempagliflozinGlucosidesHypoglycemic AgentsLinagliptinSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID36738751
PMCPMC10851109
OpenAlexW4318833121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.